Performance evaluation of stool DNA methylation tests in colorectal cancer screening: a systematic review and meta-analysis.
Adult
Biomarkers, Tumor
/ genetics
COVID-19
Colorectal Neoplasms
/ diagnosis
DNA Methylation
/ genetics
Early Detection of Cancer
/ methods
False Negative Reactions
False Positive Reactions
Feces
/ chemistry
Female
Genetic Testing
/ methods
Humans
Male
Middle Aged
Odds Ratio
SARS-CoV-2
Sensitivity and Specificity
COVID-19
DNA
colorectal cancer
genetic test
pandemic
screening
stool
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
30
12
2020
received:
20
09
2020
accepted:
30
12
2020
pubmed:
8
1
2021
medline:
18
5
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
There is not sufficient evidence about whether stool DNA methylation tests allow prioritizing patients to colonoscopy. Due to the COVID-19 pandemic, there will be a wait-list for rescheduling colonoscopies once the mitigation is lifted. The aim of this meta-analysis was to evaluate the accuracy of stool DNA methylation tests in detecting colorectal cancer. The PubMed, Cochrane Library and MEDLINE via Ovid were searched. Studies reporting the accuracy (Sackett phase 2 or 3) of stool DNA methylation tests to detect sporadic colorectal cancer were included. The DerSimonian-Laird method with random-effects model was utilized for meta-analysis. Forty-six studies totaling 16 149 patients were included in the meta-analysis. The pooled sensitivity and specificity of all single genes and combinations was 62.7% (57.7%, 67.4%) and 91% (89.5%, 92.2%), respectively. Combinations of genes provided higher sensitivity compared to single genes (80.8% [75.1%, 85.4%] vs. 57.8% [52.3%, 63.1%]) with no significant decrease in specificity (87.8% [84.1%, 90.7%] vs. 92.1% [90.4%, 93.5%]). The most accurate single gene was found to be SDC2 with a sensitivity of 83.1% (72.6%, 90.2%) and a specificity of 91.2% (88.6%, 93.2%). Stool DNA methylation tests have high specificity (92%) with relatively lower sensitivity (81%). Combining genes increases sensitivity compared to single gene tests. The single most accurate gene is SDC2, which should be considered for further research.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1030-1042Informations de copyright
© 2021 The Association of Coloproctology of Great Britain and Ireland.
Références
Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health. 2014;2:210. PMID: 25386553.
American College of Surgeons (ACS). COVID-19 update: guidance for triage of non-emergent surgical procedures. March 13, 2020. www.facs.org
American Cancer Society. Key Statistics for Colorectal Cancer. Last Revised January 8, 2020. Accessed on April 15, 2020. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256(5053):102-5.PMID: 1566048.
Pin Vieito N, Zarraquinos S, Cubiella J. High-risk symptoms and quantitative faecal immunochemical test accuracy: systematic review and meta-analysis. World J Gastroenterol. 2019;25(19):2383-401.PMID: 31148909. https://doi.org/10.3748/wjg.v25.i19.2383
Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68(14):5795-802.PMID: 18632633.
Chen B, Xia Z, Deng Y-N, Yang Y, Zhang P, Zhu H, et al. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol. 2019;9(1):180212. PMCID: PMC6367136.
Zhang H, Qi J, Wu YQ, Zhang P, Jiang J, Wang QX, et al. Accuracy of early detection of colorectal tumours by stool methylation markers: a meta-analysis. World J Gastroenterol. 2014;20(38):14040-50.
Deeks JJ, Bossuyt PM, Gatsonis C. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 1.0. London, UK: The Cochrane Collaboration; 2010. Available from: https://methods.cochrane.org/sdt/handbook-dta-reviews [Accessed on April 16, 2020].
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336-41.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
Reitsma JB, Rutjes AWS, Whiting P, et al. Chapter 9: Assessing methodological quality. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 1.0. London, UK: The Cochrane Collaboration, 2009. 1-27. https://methods.cochrane.org/sdt/handbook-dta-reviews [Accessed on April 16, 2020].
Carmona FJ, Azuara D, Berenguer-Llergo A, Fernández AF, Biondo S, de Oca J, et al. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res (Phila). 2013;6(7):656-65.
Amiot A, Mansour H, Baumgaertner I, Delchier J-C, Tournigand C, Furet J-P, et al. The detection of the methylated WIF-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening. PLoS One. 2014;9(7):e99233.
Azuara D, Rodriguez-Moranta F, de Oca J, Soriano-Izquierdo A, Mora J, Guardiola J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer. 2010;9(3):168-76.
Kim MS, Louwagie J, Carvalho B, Terhaar Sive Droste JS, Park HL, Chae YK, et al. Promoter DNA methylation of oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer. PLoS One. 2009;4(8):e6555.
Sun M, Liu J, Hu H, Guo P, Shan Z, Yang H, et al. A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population. J Cancer Res Clin Oncol. 2019;145(10):2423-32.
Park S-K, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, et al. Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res. 2017;15(4):495.
Abbaszadegan MR. Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol. 2007;13(10):1528.
Chang E, Park D, Jin Y, Kim BK, Park JH, Kim HJ, et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFPR2 and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterology. 2010;57:720-7.
Liu R, Su X, Long Y, Zhou D, Zhang X, Ye Z, et al. A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma. Mutat Res. 2019;779:45-57.
Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5(1):111-7.
Guo Q, Song Y, Zhang H, Wu X, Xia P, Dang C, et al. Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients. Med Oncol. 2013;30(4):695.
Hellebrekers DMEI, Lentjes MHFM, van den Bosch SM, Melotte V, Wouters KA, Daenen KL, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009;15(12):3990-7.
Lu H, Huang S, Zhang X, Wang D, Zhang X, Yuan X, et al. DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett. 2014;8(4):1751-6.
Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Göke B, et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005;3(2):142-9.
Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH, Park DI. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum. 2009;52(8):1452-9.
Huang Z-H. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007;13(6):950.
Melotte V, Lentjes MHFM, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, et al. N-myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009;101(13):916-27.
Xiao W, Zhao H, Dong W, Li Q, Zhu J, Li G, et al. Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer. Oncol Lett. 2015;9(3):1383-7.
Bosch LJW, Mongera S, Sive Droste JST, Oort FA, van Turenhout ST, Penning MT, et al. Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection. Cell Oncol (Dordr). 2012;35(4):309-15.
He C-G, Huang Q-Y, Chen L-S, Ling ZA, Wu HG, Deng HQ, et al. p33ING1b methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. Oncol Lett. 2014;7(5):1639-44.
Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst. 2009;101(18):1244-58.
Han YD, Oh TJ, Chung T-H, Jang HW, Kim YN, An S, et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenet. 2019;11(1):51.
Niu F, Wen J, Fu X, Li C, Zhao R, Wu S, et al. Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2017;26(9):1411-9.
Oh TJ, Oh HI, Seo YY,Jeong D, Kim C, Kang HW, et al. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenet. 2017;9(1):126.
Park YS, Kim DS, Cho SW, Park JW, Jeon SJ, Moon TJ, et al. Analysis of syndecan-2 methylation in bowel lavage fluid for the detection of colorectal neoplasm. Gut Liv. 2018;12(5):508-15.
Harada T, Yamamoto E, Yamano H, Nojima M, Maruyama R, Kumegawa K, et al. Analysis of DNA methylation in bowel lavage fluid for detection of colorectal cancer. Cancer Prev Res (Phila). 2014;7(10):1002-10.
Salehi R, Mohammadi M, Emami M, Salehi AR. Methylation pattern of SFRP1 promoter in stool sample is a potential marker for early detection of colorectal cancer. Adv Biomed Res. 2012;1(1):87.
Babaei H, Mohammadi M, Salehi R. DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA. Niger Med J. 2016;57(4):242-5.
Kriegshäuser G, Enko D, Zitt M, Oberwalder M, Oberkanins C, Öfner D, et al. Comparison of a prototype reverse hybridization assay and MethyLight for detection of SFRP2 promotor methylation in fecal DNA. Int J Biol Markers. 2017;32(4):e467-e470.
Müller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363(9417):1283-5.
Tang D, Liu J, Wang D, Yu HF, Li YK, Zhang JQ, et al. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin Invest Med. 2011;34(2):E88-95.
Wang D-R, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 2008;14(4):524-31.
Zhang H. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol. 2014;20(20):6329-35.
Zhang H, Song Y-C, Dang C-X. Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci. 2013;10(3):230-4.
Glockner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009;69(11):4691-9.
Zhang J, Yang S, Xie Y, Chen X, Zhao Y, He D, et al. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China. Cancer Epidemiol. 2012;36(1):73-7.
Yehya AH, Yusoff NM, Khalid IA, Mahsin H, Razali RA, Azlina F, et al. Pilot study of the sensitivity and specificity of the DNA integrity assay for stool-based detection of colorectal cancer in Malaysian patients. Asian Pac J Cancer Prev. 2012;13(5):1869-72.
Suehiro Y, Zhang Y, Hashimoto S, Takami T, Higaki S, Shindo Y, et al. Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal immunochemical test for haemoglobin is a promising marker for detection of colorectal neoplasia. Ann Clin Biochem. 2018;55(1):59-68.
Chen W-D, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97(15):1124-32.
Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103(11):2862-70.
Liu L, Liu C, Fotouhi O, Fan Y, Wang K, Xia C, et al. TERT promoter hypermethylation in gastrointestinal cancer: a potential stool biomarker. Oncologist. 2017;22(10):1178-88.
Leung WK, To K-F, Man EPS, Chan MW, Hui AJ, Ng SS, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 2007;102(5):1070-6.
Xiao Z, Li B, Wang G, Zhu W, Wang Z, Lin J, et al. Validation of methylation-sensitive high-resolution melting (MS-HRM) for the detection of stool DNA methylation in colorectal neoplasms. Clin Chim Acta. 2014;431:154-63.
Li W, Zhang H, Guo Q, Wu XD, Xu ZS, Dang CX, et al. Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. Dis Markers. 2015;2015:1-6.
Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142(2):248-56.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-97.
Bosch LJW, Melotte V, Mongera S, Daenen KLJ, Coupé VMH, van Turenhout ST, et al. Multitarget stool DNA test performance in an average-risk colorectal cancer screening population. Am J Gastroenterol. 2019;114(12):1909-18.
Leung W, To K, Man E, Chan MW, Bai AH, Hui AJ, et al. Detection of epigenetic changes in fecal Dra as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem. 2004;50(11):2179-82.
Kisiel JB, Yab T, Hussain FT, Taylor WR, Garrity-Park MM, Sandborn WJ, et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(5):546-54.
Kisiel JB, Klepp P, Allawi H, Taylor WR, Giakoumopoulos M, Sander T, et al. Analysis of DNA methylation at specific loci in stool samples detects colorectal cancer and high-grade dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019;17(5):914-21.e5.
Zou H, Allawi H, Cao X, Domanico M, Harrington J, Taylor WR, et al. Quantification of methylated markers with a multiplex methylation-specific technology. Clin Chem. 2012;58(2):375-83.
Kisiel JB, Yab TC, Taylor WR, Mahoney DW, Ahlquist DA. Stool methylated DNA markers decrease following colorectal cancer resection-implications for surveillance. Dig Dis Sci. 2014;59:1764-7.
Heigh RI, Yab TC, Taylor WR, Hussain FT, Smyrk TC, Mahoney DW, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS One. 2014;9(1):e85659.
Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005;11:1203-9.
Bosch LJ, Oort FA, Neerincx M, Khalid-de Bakker CA, Terhaar sive Droste JS, Melotte V, et al. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev Res. 2012;5:464-72.
Oberwalder M, Zitt M, Wontner C, Fiegl H, Goebel G, Zitt M, et al. SFRP2 methylation in fecal DNA-a marker for colorectal polyps. Int J Colorectal Dis. 2008;23:15-9.
Lind GE, Raiborg C, Danielsen SA, Rognum TO, Thiis-Evensen E, Hoff G, et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene. 2011;30(37):3967-78.
Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 2011;10:85.
Elliott G, Johnson IT, Scarll J, Dainty J, Williams EA, Garg D, et al. Quantitative profiling of CpG island methylation in human stool for colorectal cancer detection. Int J Colorectal Dis. 2013;28:35-42.
Chen J, Sun H, Tang W, Zhou L, Xie X, Qu Z, et al. DNA methylation biomarkers in stool for early screening of colorectal cancer. J Cancer. 2019;10(21):5264-71.
Ryu H, Lee J, Yang S, Park H, Choi S, Jung K-C, et al. Syndecan-2 functions as a docking receptor for promatrix metalloproteinase-7 in human colon cancer cells. J Biol Chem. 2009;284:35692-701.
Oh T, Kim N, Moon Y, Kim MS, Hoehn BD, Park CH, et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn. 2013;15(4):498-507.
Joseph DA, King JB, Richards TB, Thomas CC, Richardson LC. Use of colorectal cancer screening tests by state. Prev Chronic Dis. 2018;15:E80.
Steinwachs D, Allen JD, Barlow WE, Duncan RP, Egede LE, Friedman LS, et al. National Institutes of Health state-of-the-science conference statement: enhancing use and quality of colorectal cancer screening. Ann Intern Med. 2010;152(10):663-7.
Zorzi M, Hassan C, Capodaglio G, Narne E, Turrin A, Baracco M, et al. Divergent long-term detection rates of proximal and distal advanced neoplasia in fecal immunochemical test screening programs: a retrospective cohort study. Ann Intern Med. 2018;169(9):602-9.
Gellad ZF, Stechuchak KM, Fisher DA, Olsen MK, McDuffie JR, Ostbye T, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol. 2011;106(6):1125-34.
U.S. Preventive Services Task Force.Colorectal Cancer: Screening. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening [Accessed on May 4, 2020].
Domanico MP, Kisiel JMD, Gagrat Z, Bourne B, Allawi HT, Taylor W, et al. Novel multi-target stool DNA marker panel yields highly accurate detection of colorectal cancer and premalignant neoplasia: 325 [Abstract]. Am J Gastroenterol. 2019;114:S191.
National Institute for Health and Care Excellence. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care. Diagnostics guidance London, UK: [DG30]; 2017.Available from: https://www.nice.org.uk/guidance/dg30/resources/quantitative-faecal-immunochemical-tests-to-guide-referral-for-colorectal-cancer-in-primary-care-pdf-1053744003781 [Accessed on May 4, 2020]
Westwood M, Corro Ramos I, Lang S, Luyendijk M, Zaim R, Stirk L, et al. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2017;21(33):1-234.
Lee WC. Selecting diagnostic tests for ruling out or ruling in disease: the use of the Kullback-Leibler distance. Int J Epidemiol. 1999;28(3):521-5.
Nicholson BD, James T, Paddon M, Justice S, Oke JL, East JE, et al. Faecal immunochemical testing for adults with symptoms of colorectal cancer attending English primary care: a retrospective cohort study of 14 487 consecutive test requests. Aliment Pharmacol Ther. 2020;52(6):1031-41. https://doi.org/10.1111/apt.15969. Online ahead of print.
Loveday C, Sud A, Jones ME, Broggio J, Scott S, Gronthound F, et al. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. Gut. 2020:gutjnl-2020-321650. https://doi.org/10.1136/gutjnl-2020-321650. Online ahead of print.
Raut JR, Guan Z, Schrotz-King P, Brenner H. Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review. Clin Epigenetics. 2020;12(1):122.